Tuesday 12 November 2013

Deep Research Report: Push to Talk Telemedicine and M-Health Convergence Market Shares, Strategies, and Forecasts, Worldwide, 2013 to 2019



Push to Talk Telemedicine and M-Health Convergence: Market Shares, Strategies, and Forecasts, Worldwide, 2013 to 2019

WinterGreen Research announces that it has published a new study Push to Talk Telemedicine and M-Health Market Convergence Shares, Strategy, and Forecasts, Worldwide, 2013 to 2019. The 2013 study has 791 pages, 278 tables and figures. Worldwide markets are poised to achieve significant growth as the push to talk is used inside telemedicine systems and m-health initiatives as a way to implement ruggedized handset communications for all clinicians.

Worldwide Tele-medicine and M-health PTT push to talk device market driving forces relate to an overall trend toward clinical reimbursement addressing mobile health initiative for chronic conditions. This trend promises to become prevalent as people learn how to keep themselves healthier. Healthy behaviors such as exercise, good diet and stress management have the potential to reverse aging on a molecular level and partly restore the vitality of a person's cells.


Healthy lifestyle choices can increase the length of DNA sequences found at the end of a person's chromosomes. This shift toward wellness has stimulated the need for better communication between clinicians and patients. New sensor technology creates the opportunity for monitoring and for alerts to be send to and from at risk people who are exercising.

PTT telemedicine markets are poised to achieve significant growth as the existing telemedicine systems merge with the smart phone systems of engagement to provide a way to improve clinical care delivery to patients with chronic disease, decreasing hospitalizations and visits to the emergency room. There is a convergence of telemedicine and m-health as the patients become more responsible for their own care delivery and their own health.

There is a convergence of telemedicine and m-health as the patient uses push to talk devices in telemonitoring situations where the sensor data is transmitted to a facility, encouraging the patient to become more responsible for their own care delivery and their own health. Push to talk devices are more rugged than ordinary smart phones and are used in transport situations inside the hospital and in ambulances.

Healthcare patient, physician, and facility decision support markets are forecast based n the broad availability of smartphones combined with the IBM Watson technology that Watson offers Interactive Care Insights for Oncology. The cognitive systems use insights gleaned from the deep experience of Memorial Sloan-Kettering clinicians. Watson is positioned to permit clinicians to provide individualized treatment.

According to Susan Eustis, lead author of the WinterGreen Research team that prepared the telemedicine market research study, "Telemedicine push to talk PTT markets are evolving as smart phone devices find more uses during patient transport. During emergency transport, sensors can provide monitoring that has not previously been available. Differential diagnostic tools support differential tele-medical treatment. The decision process take into account clinical findings form the home monitoring devices and from symptoms verbally communicated in a clinical services implementation."

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/178992

Both tele-medicine and m-health contribute to healthcare delivery in the home. M-health will surely be delivered over the smart phone. Tele-medicine is evolving toward smart phone device delivery as well. The cost of tele-medicine for the US veterans administration is $1,600 per patient per annum. This is substantially less than other NIC programs and nursing home care which can easily run to $100,000 per annum. VHA's experience is that an enterprise-wide home tele-medicine implementation is an appropriate and cost-effective way of managing chronic care patients in both urban and rural settings.

Chronic disease conditions are best treated early on when there is a change in patient condition and an early intervention can make a difference. It is even better to treat them in a wellness treatment environment before there are indications of chronic disease, before symptoms develop, by addressing lifestyle issues early on.

Telemedicine delivered on proprietary devices is becoming obsolete. Kyocera is the market leader in push to talk phones for telemedicine. The Honeywell / Samsung strategic alliance represents the smart phone model that works. Telemedicine market analysis indicates that the price points are way below device costs and that companies are seeking to gain market share by working with clients.

Telemedicine push to talk PTT dedicated device and software markets at $214 million in 2012 are anticipated to reach $4.4 billion by 2019. M-Health markets related to telemedicine at $1.4 billion are anticipated to reach $1.5 trillion by 2019 due to the leveraging of 8.5 billion smart phones and 5 billion connected tablet devices all over the world.

Companies Profiled

Market Leaders

  • Kyocera
  • Samsung

Market Participants

  • Advocate Home Health
  • Aerotel Medical Systems
  • AMAC / Lifecomm
  • American Heart Association (AHA)
  • American TeleCare
  • American Telemedicine Association
  • Apple
  • AT&T
  • Athens Regional Home Health In-Home Telemonitoring Services
  • Aurora Health Care
  • Authentidate Holding
  • Axon
  • Bayer AG / Bayer HealthCare
  • Biotronik
  • Bosch Group
  • Cardiocom
  • Care Innovations / Intel® / GE
  • Columbia University
  • Connections365
  • Continua
  • Debiotech
  • Debiotech and STMicroelectronics
  • Evident Health Services
  • FuzeBox
  • Gemalto / Cinterion
  • Home Healthcare Hospice and Community Services (HCS)
  • Honeywell
  • Infopia
  • Johns Hopkins Launch Home Telemonitoring Education Initiative
  • JSC CEM Technology
  • Kiwok
  • LG
  • LifeMasters
  • Logitech / LifeSize
  • McKesson
  • MedApps
  • Medtronic
  • Montefiore / CMO
  • National Committee for Quality Assurance
  • Nonin Medical, Inc.
  • Partners Healthcare
  • Philips
  • Polycom
  • ProConnections, Inc.
  • REACH Health, Inc.
  • RS TechMedic BV
  • Samsung Apple
  • Sandata Technologies, Inc.
  • Selected Providers for Emergency Medical Care Monitoring
  • Shield Association
  • STMicroelectronics
  • TeleAtrics™
  • TouchPointCare
  • Trifecta Technologies
  • Tunstall Healthcare Group
  • University of Houston
  • Verizon Partners Healthcare
  • Verizon Technologies
  • Veteran's Administration (VA)
  • VIDAVO S.A
  • Vidyo
  • Virtual Health
  • Visiting Nurse Service Veteran's Administration (VA)
  • Viterion
  • Vodafone
  • VRI
  • Wellpoint NoninA&D Engineering / A&D Medical
  • Windstream

To buy the copy of this report, visit:  http://www.marketresearchreports.biz/analysis/178992

Check Out These Key Topics

  • Push to Talk
  • Telehealth
  • Telemedicine
  • Telemonitoring
  • CMS Telemonitoring
  • Heart disease treatment efficacy
  • Care Management
  • CMHCB
  • Health Buddy System
  • Medicare Monitoring
  • Remote patient monitoring
  • Heart failure mortality
  • Health economics
  • Heart Failure
  • Heart Diseases
  • Cardiovascular Diseases
  • Behavior CHF patient
  • Behavior Modification
  • Telemedicine
  • Hypertension monitoring
  • Chronic heart disease telemonitoring
  • Health care delivery efficacy
  • Chronic Diseases Monitoring
  • Health Services and Systems
  • Telehealth
  • DRE
  • Health Monitoring
  • Health Communication
  • Aging
  • Monitoring Technology
  • Health engagement
  • Medical innovation
  • Mobile health
  • Remote health monitoring
  • Clinical communication
  • Medical communication
  • Tele-medicine
  • Tele-health
  • Tele-monitoring
  • Chronic heart failure
  • CHF
  • Chronic heart disease
  • Remote medical support
  • Telepharmacy
  • Seniors and health
  • Diabetes Monitoring
  • Tele Medicine
  • Remote Patient Monitoring
  • Chronic Heart Failure Mortality
  • Health Economics
  • Heart Failure
  • Heart Diseases
  • Cardiovascular Diseases
  • Quality of Care
  • American Medical Group Association
  • Department of Veterans Affairs telemonitoring
  • Chronic disease management
  • Health Buddy System Healthcare telemonitoring
  • Medicare telemonitoring
  • Bosch telehealth
  • Treatment Monitoring


Latest Reports:

Apoptosis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019: http://www.marketresearchreports.biz/analysis-details/apoptosis-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019        

Apoptosis is a programmed natural process of cell death in the body which results from natural stimuli in order to protect against viral infection, unusual cell division and cells with damaged genetic material. However malfunctioning of apoptosis can trigger uncontrolled and non regulated cell death related to degenerative disorders such as Parkinson’s disease and Alzheimer’s. Defective apoptosis process has been one of the most common and leading causes for cancer wherein the affected cells instead of undergoing apoptosis continue to proliferate and mutate. Thus development of apoptosis modulating drugs has recently been witnessing spectacular growth in the treatment for cancer, CNS diseases, and chronic inflammation or autoimmunity disorders.

The global apoptosis market is categorized by:

Drug class and consumables

  • Direct apoptogens
  • First generation indirect apoptogens
  • Second generation indirect apoptogens
  • Reagents and kits

Click Here To Download Detail Report:   http://www.marketresearchreports.biz/sample/toc/176546

Indications

  • Cancer
  • Cardiovascular
  • Neurodegenerative diseases

Currently, North America dominates the global apoptosis market and is followed by Europe due to existence of huge potential for apoptosis modulating therapeutics and rising popularity of targeted cancer therapy. Emerging economies of Asia-Pacific, Latin America, Middle East and Africa are also expected to undergo rapid growth in the apoptosis market due to the rising incidences of cancer and unmet treatment needs in such developing regions.


Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019: http://www.marketresearchreports.biz/analysis-details/biological-drugs-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019       

Biological drugs are biological medical products whose active drug substance is extracted by using living organism. The active substance is derived from living organism by the usage of recombinant DNA technology. These drugs offer better treatment solutions than synthetic drugs owing to greater accuracy and fewer side effects. Biological drugs are mainly made of monoclonal antibodies (mAbs) that help to fight with the disease. Monoclonal antibodies have the capability of targeting specific area in the body that requires drug treatment hence producing accurate results. Majorly biologic drugs are given for the treatment of diseases such as HIV/AIDS, Alzheimer’s diseases, cancers and others. Moreover, biologic drugs are also expected to find a solution for the large portion of retired population which is more prone to chronic diseases. 

Global biological drugs market is growing at substantial rate owing to the drug accuracy and increase in chronic diseases. In addition, biologic drugs have shown a better outcome in long term and offer a better quality of life. There are approximately 150 biologic drugs commercially available in the markets which are being used to treat diseases such as asthma, irritable bowel syndrome, rheumatoid arthritis, cancer and others. For example, Avastin for the treatment of lung cancer and Cerezyme for Gaucher disease are commercially available and cost about USD 100,000 and USD 300,000 per year respectively. However, half of the biological drugs are about to lose their patent protection and as a result cheaper alternative biogeneric products are expected to enter in to the market. On the contrary, cost of the biologic drugs is one the major restraining factor for the growth of this market. Biologic drugs are costly as compared to other drugs but are likely to become cheaper in near future. Owing to the potential benefits of the biologic drugs they have been put on fast track FDA approval process.

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/toc/177969   

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 

  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  

This report provides comprehensive analysis of 

  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 

About Us

MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Blog: http://industry-research-reports.blogspot.com/

No comments:

Post a Comment